Novartis ups outlook on ongoing generic Diovan delay
This article was originally published in Scrip
Executive Summary
Novartis has upped its full-year sales growth forecast, and expects its core operating income to slip at a lower rate, as its blockbuster blood pressure treatment Diovan (valsartan) continues to enjoy an absence of monotherapy generic competition in the US.